WEBULL
WebtradeDownload

Implantica (OM:IMP A SDB) Could Be 17% Undervalued After FDA Approval

Simply Wall St · 1d ago

Implantica (OM:IMP A SDB) just cleared a key hurdle in the U.S. GERD treatment market, kicking off its RefluxStop launch after FDA Premarket Approval and a strong reception at the American Foregut Society meeting.

The FDA approval and AFS reception have arrived alongside sharp price momentum, with Implantica’s share price up 27.18% over the past week and 43.91% year to date. Its three year total shareholder return of 271.07% contrasts with a weaker five year total shareholder return of a 10.14% decline, suggesting enthusiasm has recently picked up again.

Scan momentum-driven health ideas alongside Implantica’s GERD push with a curated set of 133 healthcare AI stocks focused on medical technology and data-driven treatment platforms.

After a move like Implantica’s, investors usually split into two camps. Has the bulk of the rerating already played out, or do the current numbers still leave meaningful upside on the table?

Most Popular Narrative: 17% Undervalued

Against a last close of SEK74.4, the most followed narrative on Implantica points to a fair value of about SEK90, implying the market price trails those modelled assumptions.

Impending U.S. approval of RefluxStop, supported by multiple favorable FDA inspections and clear remaining requirements, is expected to unlock a significantly larger addressable market and could drive a step change in revenue growth and operating leverage as U.S. volumes scale.

See why 1 investors see Implantica as 17% undervalued.

This storyline leans heavily on aggressive growth inputs. Analysts in that framework assume revenue growth of 160.9% per year over the next three years, alongside a shift in profit margin from a deep loss today to 11.6% by 2029, in line with the Swedish medical equipment sector average used in the model.

To reach the price target within that narrative, earnings in the model need to reach €5.1m by around August 2029 and trade on a P/E of 100.6x those projected profits, which is far higher than the 29.5x multiple cited for the broader industry in the same analysis.

Despite those demanding assumptions, the Simply Wall St framework currently treats the shares as trading about 17% below its SEK90.05 fair value estimate at a discount of roughly 5% to the modelled intrinsic value of SEK78.3, while also flagging that Implantica remains loss making with reported net income of a €19.7m loss and limited current revenue of about €2.5m.

Result: Fair Value of SEK90.05 (UNDERVALUED)

Still, the bullish Implantica narrative relies on optimistic revenue and margin assumptions, while the business today reports limited €2.5m sales and a €19.7m loss.

Find out about the key risks to this Implantica narrative.

Next Steps

Sentiment around Implantica is split right now, with strong hopes meeting clear concerns, so it makes sense to move fast and pressure test the numbers yourself. To weigh both sides properly, start with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Implantica?

If you want to sharpen your edge after reviewing Implantica, do not stop here. Let the Simply Wall St screener surface opportunities you might otherwise miss.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.